| Literature DB >> 35069118 |
Jenica Acheta1, Shannon B Z Stephens1, Sophie Belin1, Yannick Poitelon1.
Abstract
Peripheral nerve injuries are common conditions that can arise from trauma (e.g., compression, severance) and can lead to neuropathic pain as well as motor and sensory deficits. Although much knowledge exists on the mechanisms of injury and nerve regeneration, treatments that ensure functional recovery following peripheral nerve injury are limited. Schwann cells, the supporting glial cells in peripheral nerves, orchestrate the response to nerve injury, by converting to a "repair" phenotype. However, nerve regeneration is often suboptimal in humans as the repair Schwann cells do not sustain their repair phenotype long enough to support the prolonged regeneration times required for successful nerve regrowth. Thus, numerous strategies are currently focused on promoting and extending the Schwann cells repair phenotype. Low-intensity ultrasound (LIU) is a non-destructive therapeutic approach which has been shown to facilitate peripheral nerve regeneration following nerve injury in rodents. Still, clinical trials in humans are scarce and limited to small population sizes. The benefit of LIU on nerve regeneration could possibly be mediated through the repair Schwann cells. In this review, we discuss the known and possible molecular mechanisms activated in response to LIU in repair Schwann cells to draw support and attention to LIU as a compelling regenerative treatment for peripheral nerve injury.Entities:
Keywords: LIPUS; LIU; Schwann cells; peripheral nerve regeneration; ultrasound
Year: 2022 PMID: 35069118 PMCID: PMC8766802 DOI: 10.3389/fncel.2021.812588
Source DB: PubMed Journal: Front Cell Neurosci ISSN: 1662-5102 Impact factor: 6.147
Experimental parameters and outcomes of in vivo studies investigating the role of LIU on peripheral nerve after injury.
| Study | Injury | Therapeutic regiment | Animal | Outcomes | ||||||||
|
|
|
|
|
|
|
|
|
|
|
| ||
|
| Crush | 500 mW/cm2, 1 Mhz | Every other day | 1 min | n.d. | Rat | M | n.d. | Increased NCV and CMAP | n.d. | n.d. | |
|
| Crush | 250 mW/cm2, 2.25 Mhz, continuous | Every other day | 1 min | 30 days | Rat | M | 7, 14, 18, 22, 24, 26, 28, 30 dpi | n.d. | n.d. | Improved from 16 to 28 dpi | n.d. |
| Crush | 400 mW/cm2, 1 Mhz, 20% pulsed | Every day | 10 min | 10 days | Rat | M | 7, 14, 21 dpi | Increased myelinated axon density at 21 dpi (STS) | n.d. | Improved at 14 and 21 dpi | n.d. | |
|
| Crush | 250 mW/cm2, 1 Mhz, continuous | Every other day | 1 min | 60 days | Rat | F | 14, 30, 45, 60 dpi | Increased myelinated axon density from 30 to 60 dpi (IHC) | Increased NCV from 30 to 60 dpi | Improved from 30 to 60 dpi | Increased expression of NGF from 30 to 60 dpi (IHC) |
|
| Crush | 500 mW/cm2, 1 Mhz, 20% pulsed | Every day | 2 min | 14 days | Mouse | n.d. | 2, 4, 6,8, 10, 12, 14 dpi | n.d. | n.d. | Improved at 14 dpi | n.d. |
|
| Crush | 400 mW/cm2, 1 Mhz, 20% pulsed | Every day | 2 min | 14 days | Rat | F | 14 dpi | n.d. | n.d. | Improved at 14 dpi | n.d. |
|
| Crush | 200 mW/cm2, 3.3Mhz, continuous | Every day | 2 min | 28 days | Rat | n.d. | 4, 7, 14, 21, 28 dpi | n.d. | Increased CMAP at 7, 21 and 28 dpi | Increased at 28 dpi | Increased expression of CNTF at 14 and 28 dpi (qPCR) |
|
| Crush | 200 mW/cm2, 1 Mhz, 20% pulsed | every day | 1 min | 30 days | Rat | M | 7, 14, 21, 28 dpi | Increased myelin thickness from 21 to 28 dpi (EM) | Increased CMAP from 21 to 28 dpi | Improved from 14 to 28 dpi | n.d. |
|
| Crush | 140 mW/cm2, 1 Mhz, 20% pulsed | 5 days per week | 5 min | 21 days | Rat | M | 3, 7, 21 dpi | Increased myelinated axon diameter and density at 21 dpi (STS & EM) | n.d. | not affected | Reduced expression of NT-3, GSK3β, TNF, IL-6, SEMA3A at 7 dpi (qPCR) |
|
| Crush | 140 mW/cm2, 1 Mhz, 20% pulsed | every day for 2 weeks, then 5 days per week | 5 min | 30 days | Rat | M | 3, 7, 14, 30 dpi | Increased axonal regrowth at 14 dpi and myelinated axon diameter, density and myelin thickness at 30 dpi (STS & EM) | n.d. | n.d. | Increased expression of BDNF at 14 dpi (qPCR) |
|
| Cut | 100 mW/cm2, 1.5 Mhz, 20% pulsed | Every day | 20 min | 12 days | Rat | M/F | 12 dpi | Increased myelin thickness and myelinated axon density at 12 dpi (STS & EM) | n.d. | n.d. | n.d. |
|
| Cut(10 mm gap)+PLGA conduit | 200 mW/cm2, 1Mhz, 20% pulsed | Every other day | 5 min | 14 days | Rat | M | 45 dpi | Increased myelinated axon density at 45 dpi (IHC) | n.d. | n.d. | n.d. |
|
| Cut(15 mm gap)+PLGA conduit | 300 mW/cm2, 1 Mhz, 20% pulsed | Every other day | 5 min | 14 days | Rat | M | 60 dpi | Increased myelinated axon density at 60 dpi (IHC) | n.d. | n.d. | n.d. |
|
| Cut(10 mm gap)+PLGA conduit | 400 mW/cm2, 1 Mhz, 20% pulsed | Once a week | 2 min | 60 days | Rat | n.d. | 30, 60 dpi | Increased myelin thickness and myelinated axon diameter at 30 and 60 dpi (STS & EM) | n.d. | n.d. | n.d. |
|
| Cut(10 mm gap)+PLGA conduit | 400 mW/cm2, 1 Mhz, 20% pulsed | Once a week | 2 min | 180 days | Rat | n.d. | 30, 60, 120 dpi | Increased myelin thickness and myelinated axon diameter from 30 to 120 dpi (STS & EM) | Increased NCV from 90 to 120 dpi | n.d. | n.d. |
|
| Cut(10 mm gap)+PLGA conduit | 300 mW/cm2, 1 Mhz, 20% pulsed | Every day | 5 min | 14 days | Rat | F | 30, 90 dpi | n.d. | Increased NCV at 90 dpi | Improved at 30 and 90 dpi | n.d. |
|
| Cut(10 mm autograft) | 250 mW/cm2, 1 Mhz, 20% pulsed | Every other day | 5 min | 90 days | Rat | M | 14, 30, 45, 60, 90 dpi | Increased myelin thickness, myelinated axon diameter and density at 90 dpi (STS & EM) | Increased CMAP at 90 dpi | Improved from 30 to 90 dpi | n.d. |
|
| Cut | 30 mW/cm2, 1.5 Mhz, 20% pulsed | Every day, or once a week | 2 min | 60 days | Rat | F | 60 dpi | not affected (IHC) | not affected | not affected | n.d. |
The studies were categorized by type of injury (crush or transection) and in chronological order. List of the LIU parameters and measured outcomes of all analyzed studies including injury type, therapeutic regimen, animal and major outcomes on peripheral nerve morphology, electrophysiology, gene expression, and functional recovery following injury. §, †, θ these studies were done by the same lab. For this table, we use the PRISMA 2020 guidelines for systematic review (
Experimental parameters and outcomes of in vitro studies investigating the role of LIU on Schwann cells in vitro.
| Study | Therapeutic regiment | Cells | Outcomes | |||||||
|
|
|
|
|
|
|
|
|
|
| |
|
| Bottom of the plate | 100 mW/cm2, 1 Mhz, 20% pulsed | Every day | 5 min | 14 days | Primary rat SC | 3.000/cm2 | Increased at day 4, 7 and 10 | n.d. | Increased NT3 expression and decreased BDNF expression at day 14 (RT-PCR) |
|
| Immersed | 300 mW/cm2, 1 Mhz, 20% pulsed | Once | 2 min | 2 days | Primary rat SC | 2.000/cm2 | Increased at day 2 | Decreased at day 1 | n.d. |
|
| Bottom of the plate | 20 mW/cm2, 1 Mhz, 20% pulsed | Every day | 10 min | 7 days | Rat SC RSC96 | 60.000/cm2 | n.d. | n.d. | Increased ErbB3, NRG1, EGR2 and MBP expression at day 1, 4 and 7 (qPCR) |
|
| Bottom of the plate | 27.500 mW/cm2† | Every day | 10 min | 5 days | primary rat SC | 2.000/cm2 | Increased at day 5 | n.d. | Increased FDF, NGF, BDNF, GDNF, p-GSK-3β, β-catenin expression at day 5 (WB) |
Listed are the key elements of all analyzed studies including therapeutic regimen, cell type and number and major outcomes on Schwann cell proliferation, apoptosis, and gene expression. †,